Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment
2018 ◽
Vol 167
◽
pp. 86-92
◽
2016 ◽
Vol 38
(3)
◽
pp. 478-484
◽
1996 ◽
Vol 153
(5)
◽
pp. 721-724
◽
1998 ◽
Vol 39
(1)
◽
pp. 160-163
◽
2008 ◽
Vol 20
(1)
◽
pp. 41-44
◽